<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83211">
  <stage>Registered</stage>
  <submitdate>26/09/2008</submitdate>
  <approvaldate>12/12/2008</approvaldate>
  <actrnumber>ACTRN12608000630314</actrnumber>
  <trial_identification>
    <studytitle>Chinese herbal medicine for Primary Dysmenorrhea.</studytitle>
    <scientifictitle>A randomised, double-blind, placebo controlled clinical trial of the effectiveness of Chinese herbal medicine in the management of primary dysmenorrhea.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Primary Dysmenorrhea</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Chinese herbal medicine extract in an oral powder form. Intervention Group 1  standard Chinese herbal formula. Intervention Group 2  Individualised Chinese herbal formula. The dosage is for 10 days per menstrual cycle for three months treatment. Taking 6g/day twice per day mixed with warm water, commencing one week prior to bleeding (between days 20-28 of the cycle) until the third day of the cycle (during menstrual bleeding). The formulation ingredients currently remain commercial-in-confidence.</interventions>
    <comparator>Matched placebo designed to look, taste and smell identical to the active interventions in an oral powder form. The dosage is for 10 days per menstrual cycle for three months treatment. Taking 6g/day twice per day mixed with warm water, commencing one week prior to bleeding (between days 20-28 of the cycle) until the third day of the cycle (during menstrual bleeding).</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Menstrual Pain Scale</outcome>
      <timepoint>Screening, weeks 4, 8, 12, 16, 20, 24, 28.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Basal Body Temperature</outcome>
      <timepoint>Daily from screening until 28 weeks after screening.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Menstrual Symptom Diary</outcome>
      <timepoint>Screening, weeks 4, 8, 12, 16, 20, 24, 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pain in the lower abdomen in relation to menstruation over at least the last three menstrual cycles.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. History of any pelvic organic disorder

2. Taking any form of contraceptive

3. Hypertension, diabetes, hepatic disorder, renal disorder, psychological diagnosis

4. Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Potential participants are screened for eligibility; if eligible the participant is enrolled and randomly allocated to one of three groups including standard formula, individualised formula or placebo. Medication randomisation is conducted by a computer at a central administration site where the trial medications are also labelled in numbered (coded) containers to maintain concealment for researchers.</concealment>
    <sequence>A computerised randomisation list was prepared by an independent researcher not involved in subject assessments.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/03/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Sydney</primarysponsorname>
    <primarysponsoraddress>Locked Bag 1797
Penrith South DC
NSW 1797</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Western Sydney</fundingname>
      <fundingaddress>Locked Bag 1797
Penrith South DC
NSW 1797</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Sunten Pharmaceutical Co. Ltd.</fundingname>
      <fundingaddress>3F, No 11 Roosevelt Rd
Sec 2 Taipei
Taiwan ROC</fundingaddress>
      <fundingcountry>Taiwan, Province Of China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>The Chinese Medicine Clinical Research Centre (CMCRC), Liverpool Hospital</othercollaboratorname>
      <othercollaboratoraddress>Cnr Elizabeth &amp; Goulburn St
Liverpool NSW 2170</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomised, double-blind placebo controlled trial in the use of Chinese herbal medicine in the management of primary dysmenorrhea in Australia. This investigation seeks to establish whether Chinese herbs offer any beneficial effect in the management of this disorder. Dysmenorrhea is a common gynaecological complaint among adolescent girls and women of reproductive age and refers to the occurrence of painful menstrual cramps of lower abdominal origin. This trial will include the assessment of Chinese herbs in standard and individual formulas against placebo.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Western Sydney Human Research Ethics Committee</ethicname>
      <ethicaddress>Locked Bag 1797
Penrith South DC
NSW 1797</ethicaddress>
      <ethicapprovaldate />
      <hrec>03/195</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>South Western Sydney Area Health Service</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>03/099</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Centre for Complementary Medicine Research (CompleMED)</name>
      <address>University of Western Sydney
Locked Bag 1797
Penrith South DC
NSW 1797</address>
      <phone>02 9772 6384</phone>
      <fax />
      <email>complemed@uws.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Centre for Complementary Medicine Research (CompleMED)</name>
      <address>University of Western Sydney
Locked Bag 1797
Penrith South DC
NSW 1797</address>
      <phone>02 9772 6384</phone>
      <fax />
      <email>complemed@uws.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>